Baird analyst Andrew Wittmann downgrades ABM Indus (NYSE:ABM) from Outperform to Neutral and lowers the price target from $52 to $51.
Merck’s Multi-Billion Cancer Drug Keytruda Improves Disease-Free Survival In Advanced Bladder Cancer After Surgery, Data Shows
Merck's Keytruda results in treating high-risk urothelial carcinoma. Discover statistically significant improvements in disease-free survival at ASCO GU Cancers Symposium 2024.